Moody Aldrich Partners LLC Reduces Stake in Verona Pharma plc (NASDAQ:VRNA)
April 5, 2023
Trending News 🌧️
Moody Aldrich Partners LLC has recently reduced its stake in Verona Pharma ($NASDAQ:VRNA) plc (NASDAQ:VRNA). The company has been embracing partnerships with a number of different players in order to expand its reach and increase its research capabilities. It has established collaborations with institutions such as The University of Pittsburgh, the University of East Anglia, the University of Southampton, and Wake Forest University. The company has also partnered with a number of global healthcare companies such as AstraZeneca, Janssen Pharmaceuticals, GlaxoSmithKline, and Novartis to develop drugs and solutions for respiratory diseases.
Furthermore, the company has entered into a licensing agreement with AstraZeneca to develop a novel inhaled therapy for the treatment of COPD. It remains to be seen how the company will progress from here and how its products will fare in the future.
Price History
On Monday, Verona Pharma plc (NASDAQ:VRNA) shares opened at $20.2 and closed at $20.8, a 3.8% increase from its previous closing price of 20.1. Investors responded positively to the news, with Verona Pharma’s share price increasing throughout the day as traders speculated on the potential impact of the stake reduction. The stock’s overall performance has been relatively consistent over the last few months, signalling investor enthusiasm for the company’s future prospects. With the reduction in ownership, Verona Pharma may be better positioned to pursue new opportunities and strategic investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Verona Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 0.46 | -68.7 | -14393.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Verona Pharma. More…
| Operations | Investing | Financing |
| -59.86 | -0.03 | 140.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Verona Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 259.47 | 29 | 3.04 |
Key Ratios Snapshot
Some of the financial key ratios for Verona Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -14831.2% |
| FCF Margin | ROE | ROA |
| -13076.6% | -18.1% | -16.4% |
Analysis
At GoodWhale, we have conducted an analysis of VERONA PHARMA‘s wellbeing and have come to the conclusion that it is a medium risk investment, based on our Risk Rating. We looked at both financial and business aspects, and found 3 risk warnings in the income sheet, balance sheet, and cashflow statement. For more information on these risk warnings, please register with us and check it out. More…
Peers
Some of its competitors are Karuna Therapeutics Inc, Cardiff Oncology Inc, Reviva Pharmaceuticals Holdings Inc.
– Karuna Therapeutics Inc ($NASDAQ:KRTX)
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatments for patients with psychiatric and neurological disorders. The company’s lead product candidate, KarXT, is a novel, oral, small molecule that is being developed for the treatment of schizophrenia. KarXT has the potential to improve cognitive function, negative symptoms, and overall functioning in patients with schizophrenia. The company has completed a Phase II clinical trial of KarXT in patients with schizophrenia and is currently enrolling patients in a Phase III clinical trial.
– Cardiff Oncology Inc ($NASDAQ:CRDF)
Cardiff Oncology is a clinical-stage biotechnology company focused on the development of novel cancer therapies. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Cardiff Oncology has a market cap of $59.42 million and a return on equity of -21.11%. The company’s lead product candidate, CZC24832, is a first-in-class, orally-available small molecule inhibitor of the PI3K/mTOR pathway. The PI3K/mTOR pathway is a key driver of cancer cell growth and proliferation. CZC24832 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Reviva Pharmaceuticals Holdings Inc ($NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 107.33M as of 2022 and a Return on Equity of -63.24%. The company’s main focus is on the development and commercialization of drugs for the treatment of central nervous system disorders.
Summary
Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases. Despite this, the stock prices rose, signaling investors optimism due to the company’s strong pipeline of drugs, which are aimed at treating a range of respiratory diseases, including asthma, cystic fibrosis, bronchitis and COPD. Verona Pharma has benefited from strong partnerships with the likes of Mylan N.V., AstraZeneca, and GSK, who are helping to develop and supply potential treatments. With the continued development of its products, Verona Pharma has the potential to become an industry leader in the sector.
